FDA New Drug Approval Times, Prescription Drug User Fees, and R&D Spending

Abstract

FDA-approval times have declined significantly since the enactment of the Prescription Drug User Fee Act (PDUFA) in 1992. As a result, present value expected returns to pharmaceutical RD thus, the social benefits of PDUFA (over and above the benefits of more rapid consumer access) are likely to be substantial.